Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading on Wednesday. Traders acquired 7,667 call options on the company. This is an increase of approximately 58% compared to the typical volume of 4,843 call options.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.27, for a total value of $71,772.69. Following the sale, the director now directly owns 7,121,322 shares in the company, valued at $44,650,688.94. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 171,682 shares of company stock valued at $1,133,471 in the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RXRX. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Farther Finance Advisors LLC grew its stake in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares during the last quarter. KBC Group NV lifted its stake in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $5.79 on Friday. The business has a 50-day simple moving average of $6.63 and a two-hundred day simple moving average of $7.53. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 52 week low of $5.62 and a 52 week high of $15.74. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -3.79 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the company posted ($0.43) earnings per share. The company’s revenue was up 147.6% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals will post -1.56 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.